MX2021015758A - Métodos de purificación para oligonucleótidos enlazados a hidratos de carbono. - Google Patents

Métodos de purificación para oligonucleótidos enlazados a hidratos de carbono.

Info

Publication number
MX2021015758A
MX2021015758A MX2021015758A MX2021015758A MX2021015758A MX 2021015758 A MX2021015758 A MX 2021015758A MX 2021015758 A MX2021015758 A MX 2021015758A MX 2021015758 A MX2021015758 A MX 2021015758A MX 2021015758 A MX2021015758 A MX 2021015758A
Authority
MX
Mexico
Prior art keywords
carbohydrate
methods
purification methods
linked oligonucleotides
purifying
Prior art date
Application number
MX2021015758A
Other languages
English (en)
Inventor
Artaches Kazarian
Wesley Barnhart
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2021015758A publication Critical patent/MX2021015758A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/02—Processes using inorganic exchangers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/04—Processes using organic exchangers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification

Abstract

La presente invención se refiere a métodos para purificar ácidos nucleicos. En partículas la presente invención se refiere a métodos para purificar oligonucleótidos conjugados con hidratos de carbono usando una fase estacionaria de modo mixto y una fase móvil que comprende un gradiente doble de sal/disolvente orgánico. Además, se describen métodos para purificar oligonucleótidos conjugados con hidratos de carbono usando una fase estacionaria de intercambio aniónico y una fase móvil que comprende un gradiente doble de pH/sal.
MX2021015758A 2019-06-25 2020-06-24 Métodos de purificación para oligonucleótidos enlazados a hidratos de carbono. MX2021015758A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962866515P 2019-06-25 2019-06-25
PCT/US2020/039462 WO2020264055A1 (en) 2019-06-25 2020-06-24 Purification methods for carbohydrate-linked oligonucleotides

Publications (1)

Publication Number Publication Date
MX2021015758A true MX2021015758A (es) 2022-04-01

Family

ID=71614959

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015758A MX2021015758A (es) 2019-06-25 2020-06-24 Métodos de purificación para oligonucleótidos enlazados a hidratos de carbono.

Country Status (7)

Country Link
US (1) US20220363711A1 (es)
EP (1) EP3990465A1 (es)
JP (1) JP2022539327A (es)
AU (1) AU2020301419A1 (es)
CA (1) CA3143047A1 (es)
MX (1) MX2021015758A (es)
WO (1) WO2020264055A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4341269A1 (en) * 2021-05-20 2024-03-27 Olix US, Inc. Functional moieties and their uses and synthetic preparation
AU2022358343A1 (en) * 2021-09-30 2024-03-28 Amgen Inc. Methods for separating molecular species of guanine-rich oligonucleotides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP2990410A1 (en) * 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
US8877917B2 (en) 2007-04-23 2014-11-04 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
EA031393B1 (ru) 2013-05-01 2018-12-28 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии hbv и ttr
US20160122761A1 (en) 2013-06-21 2016-05-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
EP3960860A3 (en) * 2014-02-11 2022-06-08 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
JP6983797B2 (ja) 2016-03-07 2021-12-17 アローヘッド ファーマシューティカルズ インコーポレイテッド 治療化合物用の標的化リガンド
UY37376A (es) 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso

Also Published As

Publication number Publication date
JP2022539327A (ja) 2022-09-08
EP3990465A1 (en) 2022-05-04
CA3143047A1 (en) 2020-12-30
WO2020264055A1 (en) 2020-12-30
AU2020301419A1 (en) 2022-01-20
US20220363711A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2018015529A (es) Etiquetado utilizando transposomas inmovilizados con ligadores.
MX2021015758A (es) Métodos de purificación para oligonucleótidos enlazados a hidratos de carbono.
WO2016161375A3 (en) Methods of using oligonucleotide-guided argonaute proteins
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
ATE384742T1 (de) Verfahren zur reinigung von preproinsulin
WO2015191911A3 (en) Protein enriched microvesicles and methods of making and using the same
FR2931824B1 (fr) Procede de synthese d'arn par voie chimique.
WO2014165818A3 (en) Compositions and methods for preventing and treating prostate cancer
ATE481482T1 (de) Verfahren zur vorbereitenden rna-reinigung mittels hplc
WO2014011753A3 (en) Anthraquinone analogs and methods of making and using thereof
EA201590195A1 (ru) Днк-кодированные библиотеки, содержащие связи кодирующих олигонуклеотидов, не доступные для считывания полимеразами
WO2012013682A3 (en) Protein purification
WO2017205277A3 (en) Methods for using nucleic acid aptamers for directed templated assembly
MX342920B (es) Metodo para purificar polipeptidos o inmunoconjugados activos.
SG11202108893SA (en) Purification process for biological molecules such as plasmid dna using anionic exchange chromatography
CN109963596A8 (zh) 长效多特异性分子和相关方法
BRPI1009576A2 (pt) anticorpo, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, uso de um anticorpo, e, método para o tratamento de um paciente.
EP4306544A3 (en) Production of heteromultimeric proteins using mammalian cells
WO2008112980A3 (en) Method and system for assembly of macromolecules and nanostructures
MX2021002745A (es) Metodos de purificacion de oligonucleotidos ricos en guanina.
WO2013028334A3 (en) Use of small molecules in methods for purification of biomolecules
WO2020106776A3 (en) Methods and compositions for preparing nucleic acids that preserve spatial-proximal contiguity information
MX2021014334A (es) Agentes afines a aav9.
MX2019006568A (es) Eliminacion de ligandos lixiviados de purificacion de afinidad.
NO20053128D0 (no) Process for preparing vanadyl pyrophosphate catalyst.